Simoa® Immunoassays Enable Ultrasensitive Detection of Blood-Based Biomarkers for Parkinson's Disease

Publication Brief

Parkinson’s disease (PD) is a progressive and debilitating neurodegenerative disorder that affects millions of people worldwide. Therapeutic management can ease symptoms and slow progression, especially if implemented in the early stages of the disease. However, traditional diagnostic methods are limited to detecting motor deficits, which may not manifest until the later stages of the disease progression. This leaves a critical gap in identifying asymptomatic patients who could benefit most from early therapeutic intervention. Download our flyer to learn more and to view a sampling of peer-reviewed studies employing Simoa® technology for Parkinson's disease research.

If you see this, do not fill:

Fill in the form below.

First Name *
Last Name *
Email *
Company *
What type of organization is your company? *
Country *
State *
Therapeutic Area
To select multiple values, hold down the Shift or Control (PC) or Command (Mac) key.
I consent

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.